Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Switzerland’s president and other top officials are traveling to Washington in a hastily arranged trip aimed at striking a ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for ...

LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Recent studies may challenge the thinking about lipoprotein(a) as a risk factor for cardiovascular events, but experts say ...

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

President Trump sent letters Thursday to 17 of the world’s largest drug companies, telling them to take more steps to slash ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Today, the regulator revealed FDA PreCheck, which introduces a two-phase approach to getting approval for new production ...